These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 27572552)

  • 21. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
    PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
    Danova M; Chiroli S; Rosti G; Doan QV
    Tumori; 2009; 95(2):219-26. PubMed ID: 19579869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
    Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
    Freyer G; Kalinka-Warzocha E; Syrigos K; Marinca M; Tonini G; Ng SL; Wong ZW; Salar A; Steger G; Abdelsalam M; DeCosta L; Szabo Z
    Med Oncol; 2015 Oct; 32(10):236. PubMed ID: 26315712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
    Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
    Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
    Barnes G; Pathak A; Schwartzberg L
    Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
    Tseng TH; Chiang SC; Hsu JC; Ko Y
    PLoS One; 2024; 19(6):e0303294. PubMed ID: 38857244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
    Clemons M; Fergusson D; Joy AA; Thavorn K; Meza-Junco J; Hiller JP; Mackey J; Ng T; Zhu X; Ibrahim MFK; Sienkiewicz M; Saunders D; Vandermeer L; Pond G; Basulaiman B; Awan A; Pitre L; Nixon NA; Hutton B; Hilton JF;
    Breast; 2021 Aug; 58():42-49. PubMed ID: 33901921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
    Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.
    Wen TJ; Wen YW; Chien CR; Chiang SC; Hsu WW; Shen LJ; Hsiao FY
    J Eval Clin Pract; 2017 Apr; 23(2):288-293. PubMed ID: 27491287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
    Van Belle H; Hurvitz SA; Gilbar PJ; Wildiers H
    Breast Cancer Res Treat; 2021 Dec; 190(3):357-372. PubMed ID: 34533681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
    Bacrie J; Laurans M; Iorio P; Fourme E; Volters AB; Bozec L; Lerebours F; Dubot C; Bensaoula O; Benzidane B; Pierga JY; Lefeuvre D
    Support Care Cancer; 2018 Dec; 26(12):4097-4103. PubMed ID: 29855772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.